NCT01504490View on ClinicalTrials.gov

Phase I Study of CS-7017 and Bexarotene

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Solid TumorsLymphomaMultiple Myeloma
Interventions
DRUG

CS-7017 and Bexarotene

"CS-7017 will be administered orally, twice daily for 28 days of each 28-day cycle in escalating doses depending on cohort patient is assigned to.~Bexarotene will be administered orally once daily for 28 days of each 28-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to."

Trial Locations (1)

20007

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.

Sponsors

Collaborators (1)

Daiichi Sankyo
All Listed Sponsors
collaborator

Daiichi Sankyo

INDUSTRY

lead

Georgetown University

OTHER